Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104)

Trial Profile

Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amrubicin (Primary) ; Granulocyte colony-stimulating factors
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 15 Jan 2013 New trial record
    • 07 Jan 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top